Abstract:Abstract Immune checkpoint blockade (ICB) targeting PD-1/PD-L1 has emerged as a revolutionizing treatment modality for multiple cancers. However, durable remission and objective response rates with ICB monotherapy remain low. Several immune resistance mechanisms have been revealed and used to develop combinational therapy. In consideration of the durable and impressive responses observed in ‘hot’ tumors, it will be valuable to make an endeavor to elucidate the tumor evasion mechanisms. Despite the well-established mechanisms in immunotherapy resistance, our study uncovered a new mechanism of tumor immune evasion through the RNA-binding protein HuR/CD147 axis. The RNA-binding protein Hu antigen R (HuR) is overexpressed in a variety of cancers and promotes tumorigenesis by interacting with a subset of oncogenic mRNAs. The tumor-associated antigen CD147, a highly glycosylated transmembrane immunoglobulin, is widely and specifically expressed in multiple malignancies. We phenotypically observed the downregulation of CD147 in HuR-deficient cells and elucidated that HuR regulates CD147 mRNA via binding to the AU-rich elements of its 3' UTR. The direct binding of HuR to CD147 mRNA in multiple types of cells was validated by Ribonucleoprotein immunoprecipitation (RNP-IP) and RNA pulldown assay. These data together clarify HuR is engaged in CD147 post-transcription regulation. KH-39 is a HuR-specific small molecule inhibitor, which disrupts the HuR function by competing for the binding site with its target mRNAs. KH-39 treatment reduced CD147 level in a time-/dose-dependent manner. We also tested the anti-tumor action of HuR small molecular inhibitor KH-39 in tumor proliferation, clonogenicity, cell death, cytokine secretion, and in vivo tumor growth. The cytokine array assay indicated multiple immune-related cytokines changed after HuR inhibition and CD147 knockdown, including IL-6, which is proven to act as an immunomodulating agent in the tumor microenvironment. These data demonstrated the potential mechanism of overcoming immunoresistance by inhibiting the HuR/CD147/IL-6 axis. To test the combination strategy using HuR inhibitor and anti-PD-1 antibody in vivo, we established the EMT6 orthotopic mouse breast cancer model. A combination of HuR inhibitor KH-39 and anti-PD-1 antibody enhanced the anti-PD1 immunotherapy response and prolonged survival compared to the single agent group. Taken together, we preliminarily explored the HuR/CD147/IL-6 axis in tumor immune evasion, which might be a promising therapeutic target to overcome immune evasion and improve immunotherapy response in cancer. This finding may have reference significance for clinical cancer therapy. Citation Format: Qi Zhang, Lauren Dandreo, Xiaoqing Wu, Liang Xu. Inhibition of HuR/CD147/IL-6 axis enhances anti-PD1 immunotherapy response in cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6646.

CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer

Integrative study reveals the prognostic and immunotherapeutic value of CD274 and PDCD1LG2 in pan-cancer

CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer

BRD4‐IRF1 axis regulates chemoradiotherapy‐induced PD‐L1 expression and immune evasion in non‐small cell lung cancer

Knockdown of CDK5 Down-Regulates PD-L1 Via the Ubiquitination-Proteasome Pathway and Improves Antitumor Immunity in Lung Adenocarcinoma

High expression of CDKN2A is associated with poor prognosis in colorectal cancer and may guide PD-1-mediated immunotherapy

CXCL5 impedes CD8+ T cell immunity by upregulating PD-L1 expression in lung cancer via PXN/AKT signaling phosphorylation and neutrophil chemotaxis

CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter

CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy

The CDK1-Related lncRNA and CXCL8 Mediated Immune Resistance in Lung Adenocarcinoma

Anlotinib enhanced CD8 + T cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer

The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage

KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8 + T-cell-dependent antitumor immunity

Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer

CDK5 Activates Hippo Signaling to Confer Resistance to Radiation Therapy Via Upregulating TAZ in Lung Cancer

lncRNA FLJ20021 regulates CDK1-mediated PANoptosis in a ZBP1-dependent manner to increase the sensitivity of laryngeal cancer-resistant cells to cisplatin

Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer

CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma

Abstract 6646: Inhibition of HuR/CD147/IL-6 axis enhances anti-PD1 immunotherapy response in cancer

CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma